It is noteworthy that most previous studies employed pharmacological inhibitors to interrogate the role of PARP1 in MS pathogenesis.[17] However, the broad expression of PARP1 in different immune and neural cell types makes it imperative to use cell‐specific approaches and probe the context‐dependent role of PARP1 in MS pathologies. The gene discussed is PARP1; the disease is myeloid sarcoma.